Monthly Publications
In Depth
Subscribe Now
In Depth
coverage of timely
Life Science
Compliance issues
Subscribe Now
Browsing Category
Pharmaceutical and Device
FDA Off-Label Hearing: Day One
Yesterday, the Food and Drug Administration (FDA) kicked off a two-day public meeting to review the extent to which off-label…
Open Payments Having an Adverse Effect on Physician-Rep Relationships
Open Payments, a program created by the Physician Payments Sunshine Act (part of the Affordable Care Act) has started to come…
Representative Lieu Laser-Focused on Device Act, Olympus
Olympus Corp. has had its fair share of legal troubles, some of which culminated in a settlement of $646 million in early 2016.…
Ubl Gets Personal, Lays Out Vision for Future of PhRMA
PhRMA President and CEO Steve Ubl recently joined the Medium blogging website and penned his first post, "Health Care Veteran…
PhRMA Members Invested $58.8 Billion in R&D in 2015
In 2015, PhRMA member companies invested $58.8 billion in research and development, up 10.3% from 2014. The new R&D data is…
CMS Final Rule on Covered Outpatient Drugs
The Centers for Medicare & Medicaid Services (CMS) issued the Covered Outpatient Drugs final rule with comment on…
A Year in Review: FDA 2015 New Drug Approvals
The approval of first-of-a-kind drugs rose last year to forty-one, resulting in the highest level of newly approved U.S.…
Sanofi Genzyme Merger Shows Future Value May Not Be All It’s Made out to Be
Merger and acquisition agreements are known to have many moving parts, and it is not uncommon for merger/acquisition…
PhRMA Disowns Companies Like Valeant and Turing
CEO of Turing has more on his plate today than ever before, as Martin Shkreli was arrested for securities violations.…
Concerns Over Valeant Lead to Troubles for Other Companies
With Valeant facing constant criticism about their business model, other pharmaceutical companies following similar…